Wells Fargo & Company MN Increases Holdings in Natus Medical Inc (BABY)

Wells Fargo & Company MN raised its position in shares of Natus Medical Inc (NASDAQ:BABY) by 24.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 99,741 shares of the medical equipment provider’s stock after acquiring an additional 19,726 shares during the quarter. Wells Fargo & Company MN’s holdings in Natus Medical were worth $3,740,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. grew its holdings in Natus Medical by 2,085.6% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,607 shares during the period. Riverhead Capital Management LLC grew its holdings in Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 1,364 shares during the period. Sei Investments Co. grew its holdings in Natus Medical by 29.7% during the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares during the period. SG Americas Securities LLC bought a new position in Natus Medical during the third quarter valued at $138,000. Finally, Victory Capital Management Inc. grew its holdings in Natus Medical by 17.6% during the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 560 shares during the period. 99.94% of the stock is owned by institutional investors and hedge funds.

Natus Medical Inc (BABY) opened at $30.40 on Tuesday. Natus Medical Inc has a twelve month low of $30.27 and a twelve month high of $43.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.21 and a quick ratio of 3.36. The company has a market capitalization of $947.09, a price-to-earnings ratio of -506.67 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.02. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The firm had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. During the same period last year, the company earned $0.39 earnings per share. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. research analysts anticipate that Natus Medical Inc will post 1.74 EPS for the current fiscal year.

In related news, VP Dong Chune Christopher Chung sold 12,642 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the sale, the vice president now owns 141,414 shares in the company, valued at $6,068,074.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William M. Moore sold 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

Several equities analysts have weighed in on BABY shares. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Tuesday, October 24th. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $46.50.

COPYRIGHT VIOLATION WARNING: “Wells Fargo & Company MN Increases Holdings in Natus Medical Inc (BABY)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/09/wells-fargo-company-mn-increases-holdings-in-natus-medical-inc-baby.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit